The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin

Biochemistry

Volumn 48, Issue 32, 2009, Pages 7575-7583

  Abraham, Sherwin J ^a   Nolet, Ryan P ^a   Calvert, Richard J ^b,c   Anderson, Lucy M ^b   Gaponenko, Vadim ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C-TERMINAL DOMAINS; CATALYTIC DOMAINS; GTPASES; IN-CELL; ISOFORMS; ISOTHERMAL TITRATION CALORIMETRY; N-TERMINAL DOMAINS; NMR TECHNIQUES; NUCLEOTIDE BINDING; PHYSIOLOGICAL PROCESS; PROTEIN-PROTEIN INTERACTIONS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION PATHWAYS; SIGNALING PATHWAYS; SPECIFIC BINDING; SPECIFIC INTERACTION;

BIOLOGY; CALCIUM; CELL MEMBRANES; CELL PROLIFERATION; PROTEINS;

SIGNAL TRANSDUCTION;

CALCIUM ION; CALMODULIN; K RAS PROTEIN; K RAS PROTEIN 4B; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CONTROLLED STUDY; DNA BINDING; HUMAN; ISOTHERMAL TITRATION CALORIMETRY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION;

BINDING SITES; CALMODULIN; HUMANS; ISOENZYMES; MODELS, MOLECULAR; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION;

EID: 68849095670     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi900769j     Document Type: Article

References (34)

1. Barbacid, M. (1987) ras genes. Annu. Rev. Biochem. 56, 779-827.
2. Kumar, R., Sukumar, S., and Barbacid, M. (1990) Activation of ras oncogenes preceding the onset of neoplasia. Science (New York) 248, 1101-1104.
3. Malkinson, A. M. (1992) Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma. Cancer Res. 52, 2670s-2676s.
4. Meuwissen, R., Linn, S. C., van der Valk, M., Mooi, W. J., and Berns, A. (2001) Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 20, 6551-6558.
5. Janssen, K. P., el-Marjou, F., Pinto, D., Sastre, X., Rouillard, D., Fouquet, C., Soussi, T., Louvard, D., and Robine, S. (2002) Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. Gastroenterology 123, 492-504.
6. Carta, C., Pantaleoni, F., Bocchinfuso, G., Stella, L., Vasta, I., Sarkozy, A., Digilio, C., Palleschi, A., Pizzuti, A., Grammatico, P., Zampino, G., Dallapiccola, B., Gelb, B. D., and Tartaglia, M. (2006) Germline missense mutations affecting KRAS isoform B are associated with a severe Noonan syndrome phenotype. Am. J. Hum. Genet. 79, 129-135.
7. Voice, J. K., Klemke, R. L., Le, A., and Jackson, J. H. (1999) Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J. Biol. Chem. 274, 17164-17170.
8. Liao, J., Wolfman, J. C., and Wolfman, A. (2003) K-ras regulates the steady-state expression of matrix metalloproteinase 2 in fibroblasts. J. Biol. Chem. 278, 31871-31878.
9. Plowman, S. J., Berry, R. L., Bader, S. A., Luo, F., Arends, M. J., Harrison, D. J., Hooper, M. L., and Patek, C. E. (2006) K-ras 4A and 4B are co-expressed widely in human tissues, and their ratio is altered in sporadic colorectal cancer. J. Exp. Clin. Cancer Res. 25, 259-267.
10. Birchenall-Roberts, M. C., Fu, T., Kim, S. G., Huang, Y. K., Dambach, M., Resau, J. H., and Ruscetti, F. W. (2006) K-Ras4B proteins are expressed in the nucleolus: Interaction with nucleolin. Biochem. Biophys. Res. Commun. 348, 540-549.
11. Liao, J., Planchon, S. M., Wolfman, J. C., and Wolfman, A. (2006) Growth factor-dependent AKT activation and cell migration requires the function of c-K(B)-Ras versus other cellular ras isoforms. J. Biol. Chem. 281, 29730-29738.
12. Rodriguez-Viciana, P., Sabatier, C., and McCormick, F. (2004) Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell. Biol. 24, 4943-4954.
13. Villalonga, P., Lopez-Alcala, C., Bosch, M., Chiloeches, A., Rocamora, N., Gil, J., Marais, R., Marshall, C. J., Bachs, O., and Agell, N. (2001) Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol. Cell. Biol. 21, 7345-7354.
14. 2+/calmodulin binds and dissociates K-RasB from membrane. Biochem. Biophys. Res. Commun. 304, 655-660.
15. 2+/ calmodulin. J. Cell Biol. 170, 429-441.
16. Bosch, M., Gil, J., Bachs, O., and Agell, N. (1998) Calmodulin inhibitor W13 induces sustained activation of ERK2 and expression of p21(cip1). J. Biol. Chem. 273, 22145-22150.
17. Villalonga, P., Lopez-Alcala, C., Chiloeches, A., Gil, J., Marais, R., Bachs, O., and Agell, N. (2002) Calmodulin prevents activation of Ras by PKC in 3T3 fibroblasts. J. Biol. Chem. 277, 37929-37935.
18. Trewhella, J. (1992) The solution structures of calmodulin and its complexes with synthetic peptides based on target enzyme binding domains. Cell Calcium 13, 377-390.
19. Ikura, M., Clore, G. M., Gronenborn, A. M., Zhu, G., Klee, C. B., and Bax, A. (1992) Solution structure of a calmodulin-target peptide complex by multidimensional NMR. Science (NewYork) 256, 632-638.
20. Qiao, M., Sheng, S., and Pardee, A. B. (2008) Metastasis and AKT activation. Cell Cycle (Georgetown, TX) 7, 2991-2996.
21. Steelman, L. S., Stadelman, K. M., Chappell, W. H., Horn, S., Basecke, J., Cervello, M., Nicoletti, F., Libra, M., Stivala, F., Martelli, A. M., and McCubrey, J. A. (2008) Akt as a therapeutic target in cancer. Expert Opin. Ther. Targets 12, 1139-1165.
22. Lopez-Alcala, C., Alvarez-Moya, B., Villalonga, P., Calvo, M., Bachs, O., and Agell, N. (2008) Identification of essential interacting elements in K-Ras/calmodulin binding and its role in K-Ras localization. J. Biol. Chem. 283, 10621-10631.
23. Hidaka, H., Sasaki, Y., Tanaka, T., Endo, T., Ohno, S., Fujii, Y., and Nagata, T. (1981) N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 78, 4354-4357.
24. Clapham, D. E. (2007) Calcium signaling. Cell 131, 1047-1058.
25. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A. (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277-293.
26. Thapar, R., Williams, J. G., and Campbell, S. L. (2004) NMR characterization of full-length farnesylated and non-farnesylated HRas and its implications for Raf activation. J. Mol. Biol. 343, 1391-1408.
27. de Rooij, J., and Bos, J. L. (1997) Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 14, 623-625.
28. Herrmann, C., Martin, G. A., and Wittinghofer, A. (1995) Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase. J. Biol. Chem. 270, 2901-2905.
29. Schlichting, I., Rapp, G., John, J., Wittinghofer, A., Pai, E. F., and Goody, R. S. (1989) Biochemical and crystallographic characterization of a complex of c-Ha-ras p21 and caged GTP with flash photolysis. Proc. Natl. Acad. Sci. U.S.A. 86, 7687-7690.
30. John, J., Schlichting, I., Schiltz, E., Rosch, P., and Wittinghofer, A. (1989) C-terminal truncation of p21H preserves crucial kinetic and structural properties. J. Biol. Chem. 264, 13086-13092.
31. Chattopadhyaya, R., Meador, W. E., Means, A. R., and Quiocho, F. A. (1992) Calmodulin structure refined at 1.7 Å resolution. J. Mol. Biol. 228, 1177-1192.
32. Wall, M. E., Clarage, J. B., and Phillips, G. N. (1997) Motions of calmodulin characterized using both Bragg and diffuse X-ray scattering. Structure 5, 1599-1612.
33. Fallon, J. L., Halling, D. B., Hamilton, S. L., and Quiocho, F. A. (2005) Structure of calmodulin bound to the hydrophobic IQ domain of the cardiac Ca(v)1.2 calcium channel. Structure 13, 1881-1886.
34. 2+-calmodulin-dependent kinase kinase. Nat. Struct. Biol. 6, 819-824.